Skip to content

Real world study of Dydrogesterone in endometriosis

A real-world prospective multicenter study to evaluate the safety and effectiveness of Dydrogesterone in endometriosis

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
CTRI
Registry ID
CTRI/2022/11/047677
Enrollment
500
Registered
2022-11-25
Start date
Unknown
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N809- Endometriosis, unspecified

Interventions

Intervention1: Dydrogesterone: 1 to 3 tablets of Dydrogesterone a day from the 5th to the 25th day of the cycle or for the entire cycle. Dosages of 10 mg several times a day should be spread over the

Sponsors

Zydus Healthcare Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Female, aged = 18 years and = 45 years. 2. Complaints on chronic pelvic pain with or without dysmenorrhea assessed by 11-items NRS. 3. External genital endometriosis confirmed by clinical evaluation, or imaging analysis (ultrasonography) of endometriotic ovarian chocolate cysts. 4. Eligible to be prescribed treatment with dydrogesterone according to labeling for treatment of endometriosis. 5. No hormonal treatment in 2 cycles before enrolment. 6. Willing to provide written informed consent

Exclusion criteria

Exclusion criteria: 1. Routine consumption of analgesics other than for the pain of endometriosis. 2. Patients receiving hormonal contraceptives in the last 2 cycles (including intrauterine devices, contraceptive patches, contraceptive rings, oral contraceptives, etc.). 3. Ongoing pregnancy. 4. Contraindications to dydrogesterone listed in the locally approved label 5. Any other condition that precludes the use of dydrogesterone in accordance with the precautions and special warnings listed in the locally approved label 6. Other conditions that made the patient’s participation impossible (based on the investigator’s decision). 7. Fertility treatments using assisted reproductive technology

Design outcomes

Primary

MeasureTime frame
Change in chronic pelvic pain intensity. The changes in chronic pelvic pain intensity assessed by 11-items Numerous Rating Scale (NRS) at the end of observation (Visit 3; 6-month follow-up) versus Baseline (Visit 1). The 11-items Numerous Rating Scale (NRS) contains the range from 0 to 10, where 0 represents no pain and 10 represents the worst pain. Patients will be asked to point the average pain intensity throughout the last month.Timepoint: Time Frame: 6 months

Secondary

MeasureTime frame
Change in chronic pelvic pain intensity on 11 item NRS Menstrual Period Check Change in dysmenorrhea ON 11 item NRS Analgesic used number of days each cycle Sexual well being on 5 point Likert ScaleTimepoint: Change in chronic pelvic pain (3 months) Menstrual period check (6 months) Change in dysmenorrhea (3 & 6 months) Analgesic use (3 & 6 month) Sexual well-being (6 month)

Countries

India

Contacts

Public ContactDr Monika Chinda

Zydus Healthcare Limited

monika.chinda@zydusife.com7777078761

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026